Evidence map›Paper›PMID 30604312›Full record

Trial reportInternational journal of hematology2019

Inhibitor development, safety and efficacy of Advate

Katsuyuki Fukutake, Masashi Taki, Tadashi Matsushita, Keiji Nogami, Midori Shima, Akira Yoshioka, Junki Takamatsu, Haruhiko Uchikawa, Hiroshi Takagi, Morio Arai and 2 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Katsuyuki FukutakeDepartment of Laboratory Medicine, Tokyo Medical University Hospital, 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. k-fukuta@qa2.so-net.ne.jp.
Masashi TakiDepartment of Pediatrics, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan.
Tadashi MatsushitaDepartment of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
Keiji NogamiDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.
Midori ShimaDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.
Akira YoshiokaDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.
Junki TakamatsuThe Japanese Red Cross Tokai Hokuriku Block Blood Center, Seto, Japan.
Haruhiko UchikawaDepartment of Clinical Scientific Writing, Shire, Tokyo, Japan.
Hiroshi TakagiDepartment of Medical Affairs, Shire, Tokyo, Japan.
Morio AraiDepartment of Medical Affairs, Shire, Tokyo, Japan.
Werner EnglDepartment of Biostatistics, Shire, Vienna, Austria.
Akira ShirahataKitakyushu Yahata-Higashi Hospital, Kitakyusyu, Japan.
Nara Medical University · JPJapanese Red Cross Society, Japan · JPKitakyushu City Yahata Hospital · JPNagoya University Hospital · JPSt. Marianna University School of Medicine · JPTokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rurioctocog alfa (recombinant factor VIII: Advate

Indexed as

Blood Coagulation Factor InhibitorsHemophilia AProduct Surveillance, PostmarketingAdolescentAdultAgedChildChild, PreschoolFactor VIIIFemaleHemorrhageHemostaticsHumansInfantJapanMaleBlood Coagulation Factor InhibitorsF8 protein, humanFactor VIIIHemostaticsAdvateHemophilia APostmarketing surveillancePreviously treated patientsRecombinant factor VIII

Identifiers

PMID30604312
OpenAlexW2883665933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.